BOURLA ALBERT 4

What Happened Albert Bourla, Chairman & CEO of Pfizer Inc., was granted 24 derivative units (phantom shares) on May 15, 2026. The units are reported at $25.33 each for a total reported value of $608. This was an award/acquisition under Pfizer’s nonfunded deferred compensation plan (not an open‑market stock purchase).

Key Details

• Transaction date: 2026-05-15; Form 4 filed: 2026-05-18 (timely filing).
• Transaction type/code: Award/Grant (A); derivative units reported.
• Price/value: 24 units × $25.33 = $608 reported value.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnotes: F1—each unit represents one phantom share of common stock. F2—units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan; they are settled in cash upon separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Context These phantom-share units are a form of deferred compensation settled in cash upon separation and do not represent immediate issuance of common stock, voting rights, or direct market exposure. Such awards are typically part of executive compensation and should be distinguished from open‑market purchases or sales when assessing insider activity.